Both in Biotechnology
Replimune Group vs Hemab Therapeutics Holdings
Over the past year REPL returned +59.8% and COAG returned +9.4%; their daily moves had a correlation of 0.37.
REPL +59.8% COAG +9.4%Growth of $1, one year, split-adjusted
| Metric | REPL | COAG |
|---|---|---|
| Price | $20.65 | $43.10 |
| Market cap | $1.96B | $2.01B |
| Today | +5.95% | +4.66% |
| 1 month | +57.0% | +40.9% |
| 6 months | +619.5% | — |
| Year to date | +112.4% | — |
| 1 year | — | — |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $183.7M | $457.5M |
| Dividend yield | — | — |
| Volatility (60d) | 77.7% | — |
| Short % of float | 29.6% | 20.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).